Literature DB >> 18946631

Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa.

Nishi Prabdial-Sing1, Adrian J Puren, Johnny Mahlangu, Peter Barrow, Sheila M Bowyer.   

Abstract

Previous studies in South African patients have shown that hepatitis C virus (HCV) prevalence is low (2.6%) and genotype 5 is the dominant genotype. This is the first sequence-based genotype study from this country on two different patient groups (haemophiliacs (H) and liver disease (LD) patients) over two time periods (2000-2002 and 2007). Genotype 5 was found to be the dominant genotype in the LD groups, but genotype 1 dominated in the H group. Genotype 2, and a higher prevalence of genotype 3a, was present in the H group when compared to previous South African studies. Genotypes 3 and 4 have been described here in the LD groups for the first time in South Africa, with subtypes 4c and 4g being identified. A separate cluster of genotype 5 sequences were found to have only one adenine at nucleotide position 107 of the 5'UTR, as previously reported. Subtyping in the less conserved NS5B region was used to further characterize the 2000-2002 isolates and validate 5'UTR typing. The study shows that by using reliable methods of genotyping, the prevalence and frequencies of HCV genotypes can be monitored in South Africa for better diagnosis and treatment of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946631     DOI: 10.1007/s00705-008-0227-2

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  6 in total

1.  Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.

Authors:  Constance N Wose Kinge; Christine Espiritu; Nishi Prabdial-Sing; Nomathamsaqa Patricia Sithebe; Mohsan Saeed; Charles M Rice
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  HCV genotypes of people with hemophilia in countries with high seroprevalances.

Authors:  J N Mahlangu; N Prabdial-Sing
Journal:  Iran Red Crescent Med J       Date:  2011-02-01       Impact factor: 0.611

3.  APASL consensus statements and management algorithms for hepatitis C virus infection.

Authors:  Masao Omata; Tatsuo Kanda; Ming-Lung Yu; Osamu Yokosuka; Seng-Gee Lim; Wasim Jafri; Ryosuke Tateishi; Saeed S Hamid; Wan-Long Chuang; Anuchit Chutaputti; Lai Wei; Jose Sollano; Shiv Kumar Sarin; Jia-Horng Kao; Geoffrey W McCaughan
Journal:  Hepatol Int       Date:  2012-03-01       Impact factor: 9.029

4.  Sequence-based in silico analysis of well studied hepatitis C virus epitopes and their variants in other genotypes (particularly genotype 5a) against South African human leukocyte antigen backgrounds.

Authors:  Nishi Prabdial-Sing; Adrian J Puren; Sheila M Bowyer
Journal:  BMC Immunol       Date:  2012-12-10       Impact factor: 3.615

5.  Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin.

Authors:  Roberto J Carvalho-Filho; Olav Dalgard
Journal:  Pharmgenomics Pers Med       Date:  2010-03-11

Review 6.  Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.

Authors:  Rajiv Shah; Lucrece Ahovegbe; Marc Niebel; James Shepherd; Emma C Thomson
Journal:  J Hepatol       Date:  2021-05-08       Impact factor: 25.083

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.